References:
1. Bild, A. H., Potti, A., and Nevins, J. R. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer, 6: 735-741, 2006.
2. Ganter, B., Snyder, R. D., Halbert, D. N., and Lee, M. D. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. Pharmacogenomics, 7: 1025-1044, 2006.
3. Martin, R., Rose, D., Yu, K., and Barros, S. Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics, 7: 1003-1016, 2006.
4. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108, 2005.
5. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182, 1987.
6. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17: 2639-2648, 1999.
7. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C. S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., and Gelber, R. D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659-1672, 2005.
8. Braun, S., Cevatli, B. S., Assemi, C., Janni, W., Kentenich, C. R., Schindlbeck, C., Rjosk, D., and Hepp, F. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol, 19: 1468-1475, 2001.
9. Zieglschmid, V., Hollmann, C., and Bocher, O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci, 42: 155-196, 2005.
10. Brown, P. UK death rates from breast cancer fall by a third. Bmj, 321: 849, 2000.
11. James, C. R., Quinn, J. E., Mullan, P. B., Johnston, P. G., and Harkin, D. P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist, 12: 142-150, 2007.
12. Osborne, C. K. Tamoxifen in the treatment of breast cancer. N Engl J Med, 339: 1609-1618, 1998.
13. Osborne, C. K., Zhao, H., and Fuqua, S. A. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol, 18: 3172-3186, 2000.
14. Fisher, B., Redmond, C., Fisher, E. R., and Caplan, R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol, 6: 1076-1087, 1988.
15. Regan, M. M. and Gelber, R. D. Predicting response to systemic treatments: learning from the past to plan for the future. Breast, 14: 582-593, 2005.
16. King, M. C., Marks, J. H., and Mandell, J. B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302: 643-646, 2003.
17. Yang, Q., Sakurai, T., Mori, I., Yoshimura, G., Nakamura, M., Nakamura, Y., Suzuma, T., Tamaki, T., Umemura, T., and Kakudo, K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer, 92: 54-60, 2001.
18. Gilmore, P. M., McCabe, N., Quinn, J. E., Kennedy, R. D., Gorski, J. J., Andrews, H. N., McWilliams, S., Carty, M., Mullan, P. B., Duprex, W. P., Liu, E. T., Johnston, P. G., and Harkin, D. P. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res, 64: 4148-4154, 2004.
19. Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M. L., Goel, A., Barbieri, V., Costanzo, F., Boland, C. R., and Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer, 88: 1285-1291, 2003.
20. Chappuis, P. O., Goffin, J., Wong, N., Perret, C., Ghadirian, P., Tonin, P. N., and Foulkes, W. D. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet, 39: 608-610, 2002.
21. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M. J. Cancer statistics, 2006. CA Cancer J Clin, 56: 106-130, 2006.
22. Johnston, P. G. Of what value genomics in colorectal cancer? Opportunities and challenges. J Clin Oncol, 22: 1538-1539, 2004.
23. Dukes, C. The classification of cancer in the rectum. J Pathol Bacteriol, 35: 323, 1932.
24. Hutter, R. V. At last--worldwide agreement on the staging of cancer. Arch Surg, 122: 1235-1239, 1987.
25. Greene, F. L. Staging of colon and rectal cancer: from endoscopy to molecular markers. Surg Endosc, 20 Suppl 2: S475-478, 2006.
26. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
27. Dotto, G. P. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta, 1471: M43-56, 2000.
28. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
29. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. p53 has a direct apoptogenic role at the mitochondria. Mol Cell, 11: 577-590, 2003.
30. Longley, D. B., Allen, W. L., and Johnston, P. G. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta, 1766: 184-196, 2006.
31. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest, 104: 263-269, 1999.
32. Fichtner, I., Slisow, W., Gill, J., Becker, M., Elbe, B., Hillebrand, T., and Bibby, M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer, 40: 298-307, 2004.
33. Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., and Jodrell, D. I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther, 3: 169-178, 2004.
34. Xi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., and Ju, J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res, 12: 2014-2024, 2006.
35. Carreras, C. W. and Santi, D. V. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem, 64: 721-762, 1995.
36. Navalgund, L. G., Rossana, C., Muench, A. J., and Johnson, L. F. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem, 255: 7386-7390, 1980.
37. Appelt, K., Bacquet, R. J., Bartlett, C. A., Booth, C. L., Freer, S. T., Fuhry, M. A., Gehring, M. R., Herrmann, S. M., Howland, E. F., Janson, C. A., and et al. Design of enzyme inhibitors using iterative protein crystallographic analysis. J Med Chem, 34: 1925-1934, 1991.
38. Danenberg, P. V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta, 473: 73-92, 1977.
39. Hardy, L. W., Finer-Moore, J. S., Montfort, W. R., Jones, M. O., Santi, D. V., and Stroud, R. M. Atomic structure of thymidylate synthase: Target for rational drug design. Science, 235: 448-455, 1987.
40. Brabender, J., Lenz, H. J., and Danenberg, P. V. Molecular markers as basis for chemotherapy? Chirurg, 71: 1433-1439, 2000.
41. Kawakami, K., Ishida, Y., Danenberg, K. D., Omura, K., Watanabe, G., and Danenberg, P. V. Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn J Cancer Res, 93: 1221-1229, 2002.
42. Kornmann, M., Link, K. H., Lenz, H. J., Pillasch, J., Metzger, R., Butzer, U., Leder, G. H., Weindel, M., Safi, F., Danenberg, K. D., Beger, H. G., and Danenberg, P. V. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett, 118: 29-35, 1997.
43. Leichman, L., Lenz, H. J., Leichman, C. G., Groshen, S., Danenberg, K., Baranda, J., Spears, C. P., Boswell, W., Silberman, H., Ortega, A., and et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer, 31A: 1306-1310, 1995.
44. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res, 6: 1322-1327, 2000.
45. Ju, J., Pedersen-Lane, J., Maley, F., and Chu, E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci U S A, 96: 3769-3774, 1999.
46. Bertucci, F., Salas, S., Eysteries, S., Nasser, V., Finetti, P., Ginestier, C., Charafe-Jauffret, E., Loriod, B., Bachelart, L., Montfort, J., Victorero, G., Viret, F., Ollendorff, V., Fert, V., Giovaninni, M., Delpero, J. R., Nguyen, C., Viens, P., Monges, G., Birnbaum, D., and Houlgatte, R. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 23: 1377-1391, 2004.
47. Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., McLeod, H. L., and Atkins, D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol, 22: 1564-1571, 2004.
48. Barrier, A., Boelle, P. Y., Roser, F., Gregg, J., Tse, C., Brault, D., Lacaine, F., Houry, S., Huguier, M., Franc, B., Flahault, A., Lemoine, A., and Dudoit, S. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol, 24: 4685-4691, 2006.
49. Eschrich, S., Yang, I., Bloom, G., Kwong, K. Y., Boulware, D., Cantor, A., Coppola, D., Kruhoffer, M., Aaltonen, L., Orntoft, T. F., Quackenbush, J., and Yeatman, T. J. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol, 23: 3526-3535, 2005.
50. Xi, Y., Nakajima, G., Schmitz, J. C., Chu, E., and Ju, J. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics, 7: 68, 2006.
51. Boyer, J., Allen, W. L., McLean, E. G., Wilson, P. M., McCulla, A., Moore, S., Longley, D. B., Caldas, C., and Johnston, P. G. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res, 66: 2765-2777, 2006.
52. Longley, D. B., Allen, W. L., McDermott, U., Wilson, T. R., Latif, T., Boyer, J., Lynch, M., and Johnston, P. G. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res, 10: 3562-3571, 2004.
53. Cummins, J. M., He, Y., Leary, R. J., Pagliarini, R., Diaz, L. A., Jr., Sjoblom, T., Barad, O., Bentwich, Z., Szafranska, A. E., Labourier, E., Raymond, C. K., Roberts, B. S., Juhl, H., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. The colorectal microRNAome. Proc Natl Acad Sci U S A, 103: 3687-3692, 2006.
54. Nakajima, G., Hayashi, K., Xi, Y., Kudo, K., Uchida, K., Takasaki, K., and Ju, J. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics & Proteomics, 3: 317-324, 2006.
55. Xi, Y., Formentini, A., Chien, M., Weir, D., Russo, J., Ju, J., Kornmann, M., and Ju, J. Prognostic Values of microRNAs in Colorectal Cancer. Biomarker Insights, 2: 113-121, 2006.
56. Michael, M. Z., SM, O. C., van Holst Pellekaan, N. G., Young, G. P., and James, R. J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 1: 882-891, 2003.
57. Akao, Y., Nakagawa, Y., and Naoe, T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 16: 845-850, 2006.
58. Akao, Y., Nakagawa, Y., and Naoe, T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull, 29: 903-906, 2006.
59. Bandres, E., Cubedo, E., Agirre, X., Malumbres, R., Zarate, R., Ramirez, N., Abajo, A., Navarro, A., Moreno, I., Monzo, M., and Garcia-Foncillas, J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer, 5: 29, 2006.
60. Harkin, D. P. Genomics and the impact of new technologies on the management of colorectal cancer. Oncologist, 11: 988-991, 2006.
61. Neal, C. P., Garcea, G., Doucas, H., Manson, M. M., Sutton, C. D., Dennison, A. R., and Berry, D. P. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer, 42: 1728-1743, 2006.
62. Ein-Dor, L., Kela, I., Getz, G., Givol, D., and Domany, E. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics, 21: 171-178, 2005.
63. Ein-Dor, L., Zuk, O., and Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A, 103: 5923-5928, 2006.
64. Hayes, K. R. and Bradfield, C. A. Advances in toxicogenomics. Chem Res Toxicol, 18: 403-414, 2005.
65. Hayes, K. R., Vollrath, A. L., Zastrow, G. M., McMillan, B. J., Craven, M., Jovanovich, S., Rank, D. R., Penn, S., Walisser, J. A., Reddy, J. K., Thomas, R. S., and Bradfield, C. A. EDGE: a centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol Pharmacol, 67: 1360-1368, 2005.
66. Dai, X., De Souza, A. T., Dai, H., Lewis, D. L., Lee, C. K., Spencer, A. G., Herweijer, H., Hagstrom, J. E., Linsley, P. S., Bassett, D. E., Ulrich, R. G., and He, Y. D. PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy. PLoS Comput Biol, 3: e30, 2007.
67. Ulrich, R. and Friend, S. H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov, 1: 84-88, 2002.
68. Ulrich, R. G. The toxicogenomics of nuclear receptor agonists. Curr Opin Chem Biol, 7: 505-510, 2003.
69. Lakkis, M. M., DeCristofaro, M. F., Ahr, H. J., and Mansfield, T. A. Application of toxicogenomics to drug development. Expert Rev Mol Diagn, 2: 337-345, 2002.
70. Goodsaid, F. and Frueh, F. Biomarker qualification pilot process at the US Food and Drug Administration. Aaps J, 9: E105-108, 2007.
71. Zerhouni, E. A., Sanders, C. A., and von Eschenbach, A. C. The Biomarkers Consortium: public and private sectors working in partnership to improve the public health. Oncologist, 12: 250-252, 2007.
72. Frueh, F. W., Goodsaid, F., Rudman, A., Huang, S. M., and Lesko, L. J. The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J, 5: 218-220, 2005.
73. Goodsaid, F. and Frueh, F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics, 7: 773-782, 2006.
74. Orr, M. S., Goodsaid, F., Amur, S., Rudman, A., and Frueh, F. W. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther, 81: 294-297, 2007.
75. Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., Kawasaki, E. S., Lee, K. Y., Luo, Y., Sun, Y. A., Willey, J. C., Setterquist, R. A., Fischer, G. M., Tong, W., Dragan, Y. P., Dix, D. J., Frueh, F. W., Goodsaid, F. M., Herman, D., Jensen, R. V., Johnson, C. D., Lobenhofer, E. K., Puri, R. K., Schrf, U., Thierry-Mieg, J., Wang, C., Wilson, M., Wolber, P. K., Zhang, L., Amur, S., Bao, W., Barbacioru, C. C., Lucas, A. B., Bertholet, V., Boysen, C., Bromley, B., Brown, D., Brunner, A., Canales, R., Cao, X. M., Cebula, T. A., Chen, J. J., Cheng, J., Chu, T. M., Chudin, E., Corson, J., Corton, J. C., Croner, L. J., Davies, C., Davison, T. S., Delenstarr, G., Deng, X., Dorris, D., Eklund, A. C., Fan, X. H., Fang, H., Fulmer-Smentek, S., Fuscoe, J. C., Gallagher, K., Ge, W., Guo, L., Guo, X., Hager, J., Haje, P. K., Han, J., Han, T., Harbottle, H. C., Harris, S. C., Hatchwell, E., Hauser, C. A., Hester, S., Hong, H., Hurban, P., Jackson, S. A., Ji, H., Knight, C. R., Kuo, W. P., LeClerc, J. E., Levy, S., Li, Q. Z., Liu, C., Liu, Y., Lombardi, M. J., Ma, Y., Magnuson, S. R., Maqsodi, B., McDaniel, T., Mei, N., Myklebost, O., Ning, B., Novoradovskaya, N., Orr, M. S., Osborn, T. W., Papallo, A., Patterson, T. A., Perkins, R. G., Peters, E. H., Peterson, R., Philips, K. L., Pine, P. S., Pusztai, L., Qian, F., Ren, H., Rosen, M., Rosenzweig, B. A., Samaha, R. R., Schena, M., Schroth, G. P., Shchegrova, S., Smith, D. D., Staedtler, F., Su, Z., Sun, H., Szallasi, Z., Tezak, Z., Thierry-Mieg, D., Thompson, K. L., Tikhonova, I., Turpaz, Y., Vallanat, B., Van, C., Walker, S. J., Wang, S. J., Wang, Y., Wolfinger, R., Wong, A., Wu, J., Xiao, C., Xie, Q., Xu, J., Yang, W., Zhang, L., Zhong, S., Zong, Y. and Slikker, W., Jr. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol, 24: 1151-1161, 2006.
76. Shi, L., Tong, W., Fang, H., Scherf, U., Han, J., Puri, R. K., Frueh, F. W., Goodsaid, F. M., Guo, L., Su, Z., Han, T., Fuscoe, J. C., Xu, Z. A., Patterson, T. A., Hong, H., Xie, Q., Perkins, R. G., Chen, J. J., and Casciano, D. A. Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics, 6 Suppl 2: S12, 2005.
77. Shi, L., Tong, W., Goodsaid, F., Frueh, F. W., Fang, H., Han, T., Fuscoe, J. C., and Casciano, D. A. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn, 4: 761-777, 2004.
78. Shi, L., Tong, W., Su, Z., Han, T., Han, J., Puri, R. K., Fang, H., Frueh, F. W., Goodsaid, F. M., Guo, L., Branham, W. S., Chen, J. J., Xu, Z. A., Harris, S. C., Hong, H., Xie, Q., Perkins, R. G., and Fuscoe, J. C. Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics, 6 Suppl 2: S11, 2005.